TARRYTOWN, N.Y.--(BUSINESS WIRE)--Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) will hold a conference call tomorrow at 10:00 AM Eastern Time to discuss the U.S. Food and Drug Administration’s approval of RELISTORTM (methylnaltrexone bromide) for subcutaneous injection. RELISTOR is indicated for the treatment of opioid-induced constipation in patients with advanced illness receiving palliative care, when response to laxatives has not been sufficient. It is the first pharmaceutical product approved for this indication in the U.S.
